Haemonetics: Q1 Earnings Insights

Shares of Haemonetics HAE moved higher by 0.1% in pre-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share were down 43.21% year over year to $0.46, which beat the estimate of $0.41.

Revenue of $195,577,000 declined by 17.98% year over year, which missed the estimate of $198,270,000.

Outlook

Haemonetics hasn't issued any earnings guidance for the time being.

Haemonetics hasn't issued any revenue guidance for the time being.

Price Action

52-week high: $140.36

52-week low: $63.41

Price action over last quarter: down 13.12%

Company Profile

Haemonetics Corp sells products used to process, handle, and analyze blood. The firm sells products in four categories: Plasma, Hemostasis Management, Blood Center and Cell Processing. The Plasma business includes plasma collection devices and disposables. Hemostasis Management includes devices and methodologies for measuring coagulation characteristics of blood, Blood Center includes blood collection and processing devices and disposables for red cells and Cell Processing include surgical blood salvage systems, specialized blood cell processing systems, disposables and blood transfusion management software.